Background and aim:In the UK, the current management of high-grade gliomas consists of maximal surgical debulking, where possible, followed by radiotherapy. A large, randomized, multicenter trial assessing the addition of temozolomide to radiotherapy found a significant increase in median survival of the order of 2.5 months in favor of the combined treatment (14.6 vs 12.1 months; p < 0.001). Our center has considerable experience with temozolomide and has treated patients with a regimen similar to that used in the above trial. The aim of this study was to confirm whether these results are translated into a benefit when used in clinical practice in the UK.
American Journal of Cancer – Springer Journals
Published: Aug 9, 2012